Brief: Tg Therapeutics Provides Preliminary Q4 And Full Year 2023 Net Revenue

TG Therapeutics

10/01/2024 12:20

Jan 10 (Reuters) - Tg Therapeutics Inc  TGTX.O :
    * TG THERAPEUTICS PROVIDES PRELIMINARY FOURTH QUARTER AND
FULL
YEAR 2023 NET REVENUE AND 2024 ANTICIPATED MILESTONES
    * PRELIMINARY U.S. BRIUMVI Q4 AND FULL YEAR 2023 NET PRODUCT
REVENUE OF APPROXIMATELY $40 MILLION AND $89 MILLION,
RESPECTIVELY
    * : PRELIMINARY YEAR-END 2023 CASH POSITION OF APPROXIMATELY
$215
MILLION
    * SEES FULL YEAR 2024 TARGET OPERATING EXPENSE OF
APPROXIMATELY
$250 MILLION
    * SEES BRIUMVI U.S. NET PRODUCT REVENUE TARGETS OF
APPROXIMATELY
$41-$46 MILLION AND $220-$260 MILLION FOR Q1 AND FULL YEAR 2024

Source text for Eikon:  ID:nGNXb5dJpW 
Further company coverage:  TGTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))